Mathes Company’s Alexion Pharmaceuticals ALXN Stock Holding History

Mathes Company’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-1,600	Closed	-$223K	–	138
2016 Q1	$223K	Hold	1,600	–	–	0.13%	118
2015 Q4	$305K	Hold	1,600	–	–	0.17%	111
2015 Q3	$250K	Hold	1,600	–	–	0.17%	113
2015 Q2	$289K	Hold	1,600	–	–	0.15%	127
2015 Q1	$277K	Hold	1,600	–	–	0.14%	139
2014 Q4	$296K	Hold	1,600	–	–	0.15%	137
2014 Q3	$265K	Hold	1,600	–	–	0.13%	144
2014 Q2	$250K	Hold	1,600	–	–	0.12%	155
2014 Q1	$243K	Hold	1,600	–	–	0.13%	152
2013 Q4	$213K	Buy	+1,600	New	+$192K	0.11%	155

Other funds holding ALXN

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Mathes Company's ALXN Position: Q2 2016 in Review

Mathes Company sold out of Alexion Pharmaceuticals (ALXN) in Q2 2016, closing a stake of 1,600 shares — an estimated $223K sold.

Mathes Company first reported a position in ALXN in Q4 2013 and held it in 10 quarters. The position peaked at $305K in Q4 2015. 534 funds tracked by Wall St. Rank hold ALXN as of Q2 2016.

Mathes Company reported no remaining Alexion Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
Mathes Company sold 1,600 Alexion Pharmaceuticals shares in Q2 2016, an estimated $223K.
Mathes Company first reported a position in Alexion Pharmaceuticals in Q4 2013 and held it in 10 quarters.
Mathes Company's Alexion Pharmaceuticals position peaked at $305K in Q4 2015.
534 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2016.

Based on Mathes Company's 13F filing for Q2 2016, filed 15 Aug 2016.